Lancet Oncol: The efficacy of the treatment of HER2-positive breast cancer with a single anti-combined pato-pearl single-dose intraseses is comparable to intravenous drug use!

On June 29, 2020, the FDA approved the combination of patojuta single resistance and curtojumo monoantigen and recombinant human hyalurase into subsurfic preparations (Patojumo monoantigen, cractum bead monoantigen and hyalurinogenase-zzxf) in a ready-to-use, fixed dose combination.
This paper reports on the pharmacodynamics, efficacy and safety results of fixed-dose off-the-cortical preparations evaluated in the FeDeriCa study and intravenous patojumal monoantigen and curto-pearl monoantigen as new complementary treatment options for HER2-positive early breast cancer patients.
FeDeriCa is a randomized, open-label, international, multi-center, non-inefficient Phase 3 trial that recruits adult patients with HER2-positive, surgical, localized late-stage or inflammatory stage II-IIIC breast cancer and requires a left cardiac shot score of ≥55%.
Subjects were randomly divided into two groups at 1:1 to receive varicose bead monoanti (840 mg load dose, followed by 420 mg maintenance dose) and venous patojumo monoanti (8 mg/kg load dose, followed by 6 mg/kg maintenance dose) or a fixed dose of Pato bead monoantigenic and curvature Bead single anti-subsultural injection (1200 mg pato bead mono-anti-600 mg curto-bead mono-load dose of 15 ml), followed by 600 mg pato-bead mono-anti-600 mg cratur bead monoantigen maintenance dose of 10 ml), are 3 weeks /course of treatment.
the patients according to hormone-subject status, clinical stage and chemotherapy program.
end of the course was the non-poor effectiveness of the ctrough concentration of two groups of patients during the 7th course.
June 14, 2018 - December 24, 2018, 252 patients were asserted to the intravenous group and 248 patients were asserted to the fixed dose group (subsuplisal group).
the geometric average ratio of serum Ctrough to the venous group was 1.22 (90% CI 1.14-1.31).
the most common level 3-4 adverse reactions were neutral granulocytosis (intravenous group vs subsuterial group: 34 cases (13 percent) vs 35 cases (14 percent)), neutral granulocyte count reduction (31 s 12 percent) vs 27 s 11 percent ), a decrease in feberative neutral granulocytes (14 s 6% vs 16 s 6%), diarrhea (12 s 5% vs 17 s 7%) and a decrease in white blood cell count (18 s 7% vs 9 s 4%).
two groups also reported at least one treatment-related adverse reaction event in 25 (10 percent, intravenous) and 26 (10 percent) patients, respectively.
deaths caused by severe adverse reactions in each of the two groups (intravenous group: urinary sepsis; subcute group: acute myocardial infarction).
In summary, the study reached its main endpoint: a fixed-dose combined cortectal injection of Patoju monoantigen and curtoju monoantigen as a new auxiliary treatment with 7 courses of efficacy, not inferior to the intravenous application of patojudium monoantigen and curtoju monoantigen, complete pathological remission rate is comparable, supporting FDA approval.
the safety of the two treatment groups was similar, consistent with other clinical trials on terroid monoantigen, patojucinoty and chemotherapy.
。